Ben Derman: Guideline on How to Think About Kidney Transplantation in Patients with Plasma Cell Disorders
Ben Derman, Assistant Professor at University of Chicago, shared a post on X about a recent article by Naoka Murakami et al. published in Kidney International:
“Excellent guideline on how to think about kidney transplantation in patients with plasma cell disorders.
- Aim for good disease control in standard-risk myeloma
- Aim for MRD negativity in high-risk myeloma
- Avoid IMiDs after transplant if possible
- Reduce immunosuppression
- For amyloid – a heme CR should be goo enough to trigger transplant
- For PGNMID – treat it empirically before transplant because you can’t monitor the disease well and relapse is common
Title: Management recommendations for kidney transplantation in patients with plasma cell dyscrasia
Authors: Naoka Murakami, Christopher Blosser, Allison Webber, Gaurav Gupta, Neeraj Singh, Samhita Boppana, Samip Master, Raviprasenna Parasuraman, Erica Campagnaro, Anuja Java, Ben Sprangers, Bhavna Bhasin-Chhabra, Erik Lum, Diala Khirfan, Priya Alexander, Miklos Molnar, Brian Benes, Ajay Kumar Thakur, Naresh Bumma, Sabine Karam, Malin Hultcrantz, Frank Bridoux, Vaishali Sanchorawala, Nelson Leung, Heather Landau
Read the Full Article on Kidney International
Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center at the University of Washington, shared this post, adding:
“This is re(n)ally awesome!!!
Well-written guidelines re: kidney transplant in myeloma et al by tour de force team: Vaishali Sanchorawala, Heather Landau, Nelson Leung et al.
Nice figures for MMsm (stratify by and MRD), MGUS, and SMM below.
MRD-neg *not* needed if standard risk.”
More posts featuring Ben Derman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023